Skip to main content
. Author manuscript; available in PMC: 2012 Mar 22.
Published in final edited form as: Mol Pharm. 2011 Feb 22;8(2):457–465. doi: 10.1021/mp1003064

Figure 3.

Figure 3

PK profiles of GH-Tf fusion proteins with different linkers. (A): The GH-Tf fusion proteins with different linkers were administered intravenously to CF1 mice via the tail vein at a dose of 4 mg/kg. (B): Fusion proteins were co-administered with GH (1.6 mg/kg). (C): Fusion proteins were co-administered with holo-Tf (240 mg/kg). Blood was collected at 5 min, 30 min, 1, 3 and 6 hours postdose and the plasma samples were analyzed by non-reducing SDS-PAGE followed by quantitative anti-Tf Western blot. The half-life was calculated by SAAM II and the values are mean ± SD from 3 to 4 mice.